Cas No. |
Product name |
487021-52-3 |
AR-A014418 |
more... |
AR-A014418 is an ATP-competitive, and selective GSK3β inhibitor with IC50 and Ki of 104 nM and 38 nM, without significant inhibition on 26 other kinases tested. |
857531-00-1 |
AT-7867 |
more... |
AT7867 is a potent ATP-competitive inhibitor of Akt1/2/3 and p70S6K/PKA with IC50 of 32 nM/17 nM/47 nM and 85 nM/20 nM, respectively; little activity outside the AGC kinase f... |
1001264-89-6 |
Ipatasertib (GDC-0068) |
more... |
Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM, 620-fold selectivity over PKA. Phase 2. |
552325-73-2 |
A-674563 |
more... |
A-674563 |
1129669-05-1 |
IM-12 |
more... |
IM-12 is a potent GSK-3β inhibitor with IC50 of 53 nM; shows a significant activity in several biological tests which was comparable or even outplayed the effects of the know... |
252935-94-7 |
CHIR-98014 |
more... |
CHIR-98014 is a selective GSK3 inhibitor with IC50s of 0.65 nM and 0.58 nM for GSK-3α and GSK-3β; potentiate insulin activation of glucose transport and utilization in vitro ... |
1056901-62-2 |
AT13148 |
more... |
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity; AKT, p70S6K, PKA, ROCK, and SGK inhibitor. |
1143532-39-1 |
AZD5636 |
more... |
AZD5363, a novel pyrrolopyrimidine-derived compound, inhibits all AKT isoforms (IC50 <10 nM). |
603288-22-8 |
LY2090314 |
more... |
LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively. |
1047634-63-8 |
Afuresertib (GSK2110183) |
more... |
GSK2110183 is an orally bioavailable, selective, ATP-competitive and potent pan-Akt inhibitor with IC50s of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively. |